I was wondering.. With a few of the larger shareh

I was wondering..
With a few of the larger shareholders on these boards (riskreturn, warp etc.) *those folks who seem to get a response when they try and communicate to Gerald..

do you think it would be worthwhile to ask our CEO the following..

we obviously have a huge retail following and most of these shareholders do not have a science background..
does Gerald realize that most "retail" eyes were on the 80 percent number and not the P value (or other statistics that the scientists following Ambs may have found significant)..

it would really help if Gerald could give some context to the "80 percent number" and let us know if he expects the new Lympro to be AT LEAST in the 90s when all is said and done..

Does Gerald understand how simple retail minds are going to look for comparisons between Lympro 1 and Lympro 2 and without any guidance does he understand why we are left with some confusion when trying to compare the two (what other numbers does he expect us to care about?)..

I know he is writing a blog early next week (Monday?).. however, it sure would be nice for this simple question to be addressed..

I know many of us would much appreciate it.. and to know bottom line whether or not they at least "expect" the numbers to meet or beat the mid 90s of Lympro 1..